| Procedures
Written informed consent was obtained in accordance with the ethical standards of the Institutional Review Board, 28 The frequency of treatment-emergent syndromal and subsyndromal hypomanic symptoms was assessed via telephone reports as well as by clinician-elicited information regarding mood conversion symptoms at each study visit, using the YMRS. In addition to the DSM-IV definition of hypomania, we employed three definitions of sub-syndromal hypomania that differ in the number and duration of symptoms. [2] [3] [4] Sub-syndromal episodes were defined as: (i) type I subsyndromal hypomania with ≥4 symptoms lasting ≤3 days; (ii) type II sub-syndromal hypomania with ≤3 symptoms lasting ≥4 days; or (iii) type III sub-syndromal hypomania with ≤3 symptoms lasting ≤3 days.
| Outcome measures
For the acute phase of treatment, outcomes included the proportion of rapid-cycling subjects who responded, as well as the proportion of subjects who experienced DSM-IV syndromal hypomania or any sub-syndromal hypomanic episode (as described above). For the continuation phase of the study, the outcomes were the proportion of subjects experiencing depressive relapse during continuation monotherapy, and the emergence of syndromal and sub-syndromal hypomanias. Generally, our aim was to compare the predictive validity of the DSM-IV definition to the predictive validity of the lifetime average definition of rapid cycling. 22 To do this, we examined four distinctions between subjects: (i) subjects who met neither definition of rapid cycling (i.e., "nonrapid cyclers"); (ii) subjects who met only DSM-IVdefined rapid cycling (i.e., "DSM-IV-only rapid cyclers"); (iii) subjects who met only lifetime-defined rapid cycling (i.e., "lifetime-only rapid cyclers"); and (iv) subjects who met DSM-IV and lifetime criteria alike for rapid cycling (i.e., "both definition" rapid cyclers).
| Statistical procedures
Initial analyses summarized demographic and clinical variables at baseline between the four groups. Differences in variables between rapid-cycling definitions and between rapid-and nonrapid-cycling groups were explored using Fisher's exact test for categorical variables and analysis of variance for continuous variables.
For tests of symptom reduction or treatment-emergent subsyndromal hypomanic episodes, we used nonrapid cyclers as a reference group against which to test the clinical outcomes of subjects who met the criteria for both definitions of rapid cycling, or those who met the criteria for one definition of rapid cycling but not the other.
Differential response, remission, and sub-syndromal hypomanic episodes between groups were ascertained using logistic regression analyses. Hazard ratios quantifying relapse were estimated using the Cox regression test. Owing to the limited number of subjects who met the criteria for one definition of rapid cycling but not the other, we did not formally test interactions with treatment. However, our results did not suggest any differences between the treatments in the effects of rapid-cycling status on clinical outcomes.
| RESULTS

| Enrollment
One-hundred twenty-nine subjects with bipolar II depression were enrolled. There was moderate agreement (κ=0.56) between the two definitions of rapid cycling. Fifty-six subjects (43.4%) met the DSM-IV-defined criteria and 60 subjects (46.5%) the lifetime-defined criteria for rapid cycling. Forty-four subjects (34.10%) met the criteria for both definitions, while 12 subjects met only the DSM-IV rapid-cycling criteria (9.3%) and 16 subjects met only the lifetime rapid-cycling criteria (14.7%). Fifty-seven subjects (44.18%) met neither definition for rapid cycling.
Subjects who met the criteria for both rapid-cycling definitions or who met only the lifetime definition tended to have a history of more prior depressive episodes and more hypomanic episodes (Table 1) .
By contrast, subjects who met the criteria for both rapid-cycling 
| Continuation treatment
| Hypomanic symptoms
| Acute treatment
Compared to the rate of treatment-emergent hypomanic symptoms (ascertained by the YMRS) in nonrapid-cycling subjects (7.02%), rates of hypomanic symptoms were not significantly different in rapidcycling subjects who met only the DSM-IV definition (0%, χ 
=0.05, P=.83).
There were also no differences between treatment conditions in the rates of treatment-emergent hypomanic symptoms or sub-syndromal hypomanic episodes.
| Continuation treatment
No syndromal hypomanic episodes occurred during the continuation phase of the study. Sub-syndromal hypomanic episodes occurred exclusively among subjects meeting lifetime-defined rapid-cycling criteria. The rates of sub-syndromal hypomanic episodes were 0.0%
for nonrapid-cycling subjects, 0.0% for subjects who met only DSM-IV-defined rapid cycling, 16.7% for subjects who met only lifetimedefined rapid cycling, and 27.8% for subjects who met both definitions for rapid cycling.
| DISCUSSION
We it is a distinct specifier of bipolar disorder). In this regard, rapid cycling may be more frequent in younger individuals, 8, 33 with diminishing frequency in older age; in addition, rapid cycling may be intermittent in character or present for years, but absent in the preceding 12 months.
Thus, a rapid-cycling individual without at least four affective episodes in the preceding year would not meet the conventional DSM-IV definition of rapid cycling.
To avoid this, we employed the definition of an average of ≥4 episodes per year over the lifetime course of the illness. [2] [3] [4] 22 This definition was designed to capture individuals who had more chronic histories of rapid mood-cycling. It comports more closely with "real world" characterization of the rapid-cycling syndrome, especially in bipolar II disorder, where the symptom course may be either intermittent or continuous for years, but absent in the preceding 12 months.
One naturalistic study of 109 bipolar patients followed up to 36 years
Non-RC (n=57) DSM-IV (n=12) Lifetime (n=16)
Both DSM-IV and lifetime (n=44) P-value n (%) n (%) n (%) n (%) reported that one-third of rapid-cycling patients recovered from rapidcycling syndrome, 14 while another prospective study 15 reported the presence of rapid-cycling status in 51% of patients taking an antidepressant, with a spontaneous recovery rate of 37% during antidepressant use. Thus, some experts have suggested changes to the definition of rapid cycling that expand the time frame beyond the preceding 12 months, 14 and some research suggests greater predictive validity of the DSM-IV definition of rapid cycling in individuals with severe manic symptoms 34 or with more mood conversion episodes in the preceding year than the DSM-IV definition requires. 32 Our results suggest few differences between the average lifetime and DSM-IV definitions of rapid cycling, although the lifetime definition was somewhat superior in identifying subjects with sub-syndromal hypomanic episodes over time. The DSM-IV definition appeared to be contaminated with severity of current hypomanic symptoms.
Several caveats should be considered when interpreting the present findings. The study was exploratory in nature and not specifically powered to detect statistically significant differences in effectiveness or mood conversion rates between different definitions of rapid cycling. It was limited to subjects with bipolar II disorder and was based upon data derived from a single-site study. It is possible that our results would be different if we included subjects with bipolar I disorder or if our sample size was substantially larger. In this regard, however, we would also note that the present study may represent one of the largest sample sizes of bipolar II subjects studied to date that examined different definitions of rapid cycling.
In particular, we note that the number of patients fitting one definition and not the other is limited, and this makes comparison between definitions difficult. Thus, our analyses, especially in the continuation phase of the study, should be interpreted with caution. While we note that the kappa statistic suggests a moderate level of agreement between rapid-cycling definitions, it also implies a certain degree of difference between the definitions. However, we acknowledge that the limited sample size makes a definitive assessment of the difference in predictive validity of outcomes difficult. Our current analyses may thus be taken to suggest that if differences exist between the definitions, they are probably not large.
It should be pointed out that the results of the present exploratory analysis were not definitive. The failure to identify a significant difference between the two defined rapid-cycling groups does not mean that differences do not exist. Larger sample sizes would be needed to detect small differences in effectiveness and mood conversion rates between groups.
We also note that our definition of rapid cycling was based upon an average lifetime frequency of ≥4 episodes per year over the course of the illness, and that this definition is as arbitrary as that of the DSM IV definition. It is also possible that the frequency of treatment-emergent manic symptoms during acute and continuation monotherapy in the current study may have differed between rapid-cycling groups if we had studied subjects with bipolar I disorder or subjects administered other antidepressant therapies.
Finally, it should be noted that a lower maximum daily dose of venlafaxine may have produced fewer hypomanic symptoms; however, the overall rate of treatment-emergent hypomanic symptoms was similar in both the venlafaxine and lithium conditions. Moreover, the relatively low mood conversion rate among both definition groups may have resulted from the inclusion of more mildly ill individuals with a lower propensity for antidepressant-induced hypomanic symptoms.
Future work should further explore diagnostic and other predictors of effectiveness and hypomania in larger populations of subjects with rapid-and nonrapid-cycling bipolar II disorder.
| CONCLUSIONS
Although not definitive, the results from the present study comport with the findings from our prior trials 22 and suggest that rapid-cycling status does not predict a poor response to either venlafaxine or lithium monotherapy, irrespective of the definition used to categorize rapidcycling syndrome. Moreover, the results suggest that the lifetime definition of rapid cycling may be more valid in characterizing the syndrome, in that it was superior in predicting sub-syndromal hypomanic episodes and was not contaminated by current hypomanic symptoms.
